Cargando…
MCP-1 targeting: Shutting off an engine for tumor development
A large amount of research has proven that monocyte chemotactic protein-1 (MCP-1) is associated with different types of disease, including autoimmune, metabolic and cardiovascular diseases. In addition, several studies have found that MCP-1 is associated with tumor development. MCP-1 expression leve...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630816/ https://www.ncbi.nlm.nih.gov/pubmed/34868363 http://dx.doi.org/10.3892/ol.2021.13144 |
_version_ | 1784607437225984000 |
---|---|
author | Wang, Liang Lan, Jinxin Tang, Jiaping Luo, Na |
author_facet | Wang, Liang Lan, Jinxin Tang, Jiaping Luo, Na |
author_sort | Wang, Liang |
collection | PubMed |
description | A large amount of research has proven that monocyte chemotactic protein-1 (MCP-1) is associated with different types of disease, including autoimmune, metabolic and cardiovascular diseases. In addition, several studies have found that MCP-1 is associated with tumor development. MCP-1 expression level in the tumor microenvironment is associated with tumor development, including in tumor invasion and metastasis, angiogenesis, and immune cell infiltration. However, the precise mechanism involved is currently being investigated. MCP-1 exerts its effects mainly via the MCP-1/C-C motif chemokine receptor 2 axis and leads to the activation of classical signaling pathways, such as PI3K/Akt/mTOR, ERK/GSK-3β/Snail, c-Raf/MEK/ERK and MAPK in different cells. The specific mechanism is still under debate; however, target therapy utilizing MCP-1 as a neutralizing antibody has been found to have a detrimental effect on tumor development. The aim of the present review was to examine the effect of MCP-1 on tumor development from several aspects, including its structure, its involvement in signaling pathways, the participating cells, and the therapeutic agents targeting MCP-1. The improved understanding into the structure of MCP-1 and the mechanism of action may facilitate new and practical therapeutic agents to achieve maximum performance in the treatment of patients with cancer. |
format | Online Article Text |
id | pubmed-8630816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-86308162021-12-03 MCP-1 targeting: Shutting off an engine for tumor development Wang, Liang Lan, Jinxin Tang, Jiaping Luo, Na Oncol Lett Review A large amount of research has proven that monocyte chemotactic protein-1 (MCP-1) is associated with different types of disease, including autoimmune, metabolic and cardiovascular diseases. In addition, several studies have found that MCP-1 is associated with tumor development. MCP-1 expression level in the tumor microenvironment is associated with tumor development, including in tumor invasion and metastasis, angiogenesis, and immune cell infiltration. However, the precise mechanism involved is currently being investigated. MCP-1 exerts its effects mainly via the MCP-1/C-C motif chemokine receptor 2 axis and leads to the activation of classical signaling pathways, such as PI3K/Akt/mTOR, ERK/GSK-3β/Snail, c-Raf/MEK/ERK and MAPK in different cells. The specific mechanism is still under debate; however, target therapy utilizing MCP-1 as a neutralizing antibody has been found to have a detrimental effect on tumor development. The aim of the present review was to examine the effect of MCP-1 on tumor development from several aspects, including its structure, its involvement in signaling pathways, the participating cells, and the therapeutic agents targeting MCP-1. The improved understanding into the structure of MCP-1 and the mechanism of action may facilitate new and practical therapeutic agents to achieve maximum performance in the treatment of patients with cancer. D.A. Spandidos 2022-01 2021-11-19 /pmc/articles/PMC8630816/ /pubmed/34868363 http://dx.doi.org/10.3892/ol.2021.13144 Text en Copyright: © Wang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Wang, Liang Lan, Jinxin Tang, Jiaping Luo, Na MCP-1 targeting: Shutting off an engine for tumor development |
title | MCP-1 targeting: Shutting off an engine for tumor development |
title_full | MCP-1 targeting: Shutting off an engine for tumor development |
title_fullStr | MCP-1 targeting: Shutting off an engine for tumor development |
title_full_unstemmed | MCP-1 targeting: Shutting off an engine for tumor development |
title_short | MCP-1 targeting: Shutting off an engine for tumor development |
title_sort | mcp-1 targeting: shutting off an engine for tumor development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630816/ https://www.ncbi.nlm.nih.gov/pubmed/34868363 http://dx.doi.org/10.3892/ol.2021.13144 |
work_keys_str_mv | AT wangliang mcp1targetingshuttingoffanenginefortumordevelopment AT lanjinxin mcp1targetingshuttingoffanenginefortumordevelopment AT tangjiaping mcp1targetingshuttingoffanenginefortumordevelopment AT luona mcp1targetingshuttingoffanenginefortumordevelopment |